These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33551421)

  • 1. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation].
    Yamazaki R; Koda Y; Abe R; Sakurai M; Kikuchi T; Kato J; Ouchi T; Mikami S; Mori T
    Rinsho Ketsueki; 2021; 62(1):25-29. PubMed ID: 33551421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
    Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
    Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukaemic relapse of anaplastic large cell lymphoma, ALK negative.
    Karki NR; Badin K; Savage N; Bryan L
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
    Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
    J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
    Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
    Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful long-term control of recurrent primary central nervous system anaplastic large cell lymphoma after autologous hematopoietic stem cell transplantation with concurrent whole brain and spinal cord radiotherapy].
    Hiroshima Y; Kaiume H; Kirihara T; Takeda W; Kurihara T; Sato K; Shimizu I; Ueki T; Sumi M; Ueno M; Ichikawa N; Asano N; Watanabe M; Kobayashi H
    Rinsho Ketsueki; 2015 Dec; 56(12):2477-82. PubMed ID: 26725359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
    Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant.
    Jagasia M; Morgan D; Goodman S; Hamilton K; Kinney M; Shyr Y; Stein R; Zic J; Greer J
    Leuk Lymphoma; 2004 Nov; 45(11):2261-7. PubMed ID: 15512815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
    Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
    Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
    Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
    BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.